Lexaria Bioscience (LEXX) Competitors

Cellectis (NASDAQ:CLLS) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, community ranking, analyst recommendations and institutional ownership.

Does the MarketBeat Community favor CLLS or LEXX?

Cellectis received 407 more outperform votes than Lexaria Bioscience when rated by MarketBeat users. However, 100.00% of users gave Lexaria Bioscience an outperform vote while only 65.09% of users gave Cellectis an outperform vote.

Company	Underperform	Outperform
Cellectis	Outperform Votes 414 65.09%	Underperform Votes 222 34.91%
Lexaria Bioscience	Outperform Votes 7 100.00%	Underperform Votes No Votes

Does the media favor CLLS or LEXX?

In the previous week, Lexaria Bioscience had 1 more articles in the media than Cellectis. MarketBeat recorded 7 mentions for Lexaria Bioscience and 6 mentions for Cellectis. Cellectis' average media sentiment score of 0.71 beat Lexaria Bioscience's score of -0.03 indicating that Cellectis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexaria Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has higher earnings and valuation, CLLS or LEXX?

Lexaria Bioscience has lower revenue, but higher earnings than Cellectis. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$41.51M	2.10	-$101.06M	-$0.83	-1.89
Lexaria Bioscience	$525.92K	39.23	-$5.80M	-$0.59	-1.99

Do analysts recommend CLLS or LEXX?

Cellectis currently has a consensus target price of $7.00, indicating a potential upside of 345.86%. Lexaria Bioscience has a consensus target price of $7.00, indicating a potential upside of 495.74%. Given Lexaria Bioscience's higher possible upside, analysts clearly believe Lexaria Bioscience is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Lexaria Bioscience	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders & institutionals have more ownership in CLLS or LEXX?

63.9% of Cellectis shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 16.4% of Cellectis shares are owned by company insiders. Comparatively, 26.4% of Lexaria Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Which has more volatility & risk, CLLS or LEXX?

Cellectis has a beta of 3.22, suggesting that its stock price is 222% more volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.

Is CLLS or LEXX more profitable?

Cellectis has a net margin of -234.39% compared to Lexaria Bioscience's net margin of -1,473.04%. Cellectis' return on equity of -74.55% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-234.39%	-74.55%	-22.65%
Lexaria Bioscience	-1,473.04%	-88.88%	-83.59%

Summary

Cellectis beats Lexaria Bioscience on 10 of the 17 factors compared between the two stocks.